PMC:6730630 / 14250-15320 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6730630","sourcedb":"PMC","sourceid":"6730630","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6730630","text":"PDSA Cycle 1\nSTUDY: 51 patients were reviewed in the pharmacist-led clinic during the first year of the project. The use of ACEI (or ARB) increased from 89% in the baseline audit (n=51/57) to 94% (n=48/51). The mean percentage of ACEI (or ARB) target dose also increased from 44% in the baseline audit to 72%, with 57% (n=29/51) patients achieving the full ACEI (or ARB) target dose compared with 21% in the baseline audit (n=12/57). The use of beta-blockers increased from 82% in the baseline audit (n=47/57) to 96% (n=49/51). The mean percentage of beta-blocker target dose also increased from 31% in the baseline audit to 56%, with 29% (n=15/51) of patients achieving the full beta-blocker target dose, compared with 7% (n=4/57) in the baseline audit. The results were published in abstract form.17\nACT: The service steering group in collaboration with the local strategic cardiology planning committee endorsed a plan to roll the clinics out across all hospital sites in the health authority and to widen the inclusion criteria to include all grades of LVSD post-MI.","divisions":[{"label":"title","span":{"begin":0,"end":12}},{"label":"p","span":{"begin":13,"end":801}}],"tracks":[]}